FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded

This Document Has Been Replaced By: Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011

FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

May 28, 2010
By United States. Advisory Committee on Immunization Practices. ...
Source: MMWR. Morbidity and mortality weekly report. 2010; 59(20):630-2.

[PDF-238.98 KB]

English

Details You May Also Like

Details:

Alternative Title:

MMWR. Morbidity and mortality weekly report
Corporate Authors:

United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.)

United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) Less -
Description:

To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the literature on sexually transmitted disease treatment, assembled tables of evidence, and listed key questions on therapeutic outcome: microbiologic cure, alleviation of symptoms, and prevention of sequelae and transmission. At a meeting with external experts, evidence was systematically assessed and guidelines developed. Quality of evidence for microbiologic cure was generally good for gonorrhea and chlamydia, poor for syphilis, and fair for most other diseases. Evidence on preventing sequelae and transmission was limited. The Guidelines include new recommendations for single-dose oral therapy of gonorrhea (cefixime, ciprofloxacin, and ofloxacin), chlamydia (azithromycin), and chancroid (azithromycin); outpatient therapy of pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole); and patient-applied therapy of genital warts (podofilox). Syphilis therapy did not change substantially. Several global issues that emerged during the development of the World Health Organization Recommendations for the Management of Sexually Transmitted Diseases also are discussed. This evidence-based approach clarified important treatment issues and the rationale for recommendations, and identified research priorities.
Subjects:

[+]

Adolescent Adult Advisory Committees Child Clinical Trials As Topic Condylomata Acuminata Human Papillomavirus 6 Human Papillomavirus 11 Humans Immunization Schedule Licensure Male Papillomavirus Infections Papillomavirus Vaccines Young Adult
Source:

MMWR. Morbidity and mortality weekly report. 2010; 59(20):630-2.
Pubmed ID:

20508594
Document Type:

Journal Article
Name as Subject:

United States. Food and Drug Administration. ; United States. Food and Drug Administration.

United States. Food and Drug Administration. ; United States. Food and Drug Administration. Less -
Place as Subject:

United States
Volume:

59
Issue:

20
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha256:cd53c14c6023cde5b61e0ec5a5c309ccd5fdd45bd6856796b6e363a20abc47f9
Download URL:

https://stacks.cdc.gov/view/cdc/7334/cdc_7334_DS1.pdf
File Type:

No Additional Files

More +

Superseded

FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

Details:

Supporting Files

You May Also Like